BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials. This move adds Compass, a cloud-based site scoring tool to the robust BioClinica eClinical platform.

By combining the Compass technology with its experience in clinical trial management, BioClinica will now offer a comprehensive "Intelligent Monitoring" solution which will enable pharmaceutical companies and contract research organizations (CROs) to embrace the reduced source documentation approach outlined by the FDA.

BioClinica President and Chief Executive Officer Mark Weinstein said, "Ever since the FDA issued its final guidance to industry on risk-based monitoring last year, there's been an explosion of interest in technology to make it a reality. Compass provides a transformative risk-based monitoring solution that enables the industry to move forward."

President and Co-founder of Blueprint Clinical, Courtney McBean added, "Compass is a powerful and proven tool that enables you to monitor what matters, when it matters. It's an intelligent monitoring solution that replaces 100 percent source data verification with greater use of off-site and central monitoring."

Compass is used to evaluate potential risks to patient safety and clinical trial operational performance. It assigns a performance-based score to each investigative site based on a combination of quantitative data and qualitative information. It is flexible and adaptable to each sponsors' needs and is responsive to the complex and dynamic nature of clinical trial designs. Compass accounts for factors unique to the study protocol and investigational drug. Compass provides information that enables sponsors and CROs to adjust their monitoring and focus attention on those sites needing extra support. Among the benefits of using Compass are optimized site quality performance, reduced costs, and effective use of monitoring resources.

Compass leverages data from a sponsor's existing Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS) whether BioClinica Express, OnPoint, or other eClinical systems. This extends the value of sponsors' existing investments while supporting integrated monitoring without redundant data collection.

McBean, who will be joining BioClinica with her team to direct Compass implementation remarked, "I am thrilled that the Compass technology is now part of BioClinica's exceptional eClinical Platform."

BioClinica is excited to add the Compass product to their Best-in-class eClinical Solutions, including:

  • Express EDC: Electronic Data Capture in a web-based solution that creates efficient processes while capturing clean real-time data at the source. Express includes tools for fast-track study build and change management, deep operational visibility, and targeted monitoring.
  • OnPoint CTMS: The Office-Smart Clinical Trial Management System that leverages Microsoft applications for the ultimate CTMS experience. It aligns clinical operations and business processes for end-to-end efficiency across the entire trial lifecycle. It provides large-scale user access without expensive licensing fees.
  • Optimizer: Powerful forecasting, simulation and demand planning technology for managing global logistics of the clinical supply chain. Optimizer Enterprise Suite includes a streamlined cloud-based tool for essential modeling and planning, a robust desktop solution for extended forecasting and planning, and Aggregator for enterprise demand planning and visibility into the global supply chain.
  • Trident IRT: The parameter-driven IRT with unprecedented performance and functionality. It accelerate study protocol setup and deployment and enables study personnel to accomplish complex subject randomization and drug dosing, tracking and reconciliation using a single powerful tool.

Industry professionals can get a first-hand look at Compass and BioClinica's other eClinical Solutions and Medical Imaging and Cardiac Safety services at the Drug Information Association (DIA) Annual Meeting. BioClinica will provide demonstrations in its exhibit in Booth 1725 at the San Diego Convention Center until June 18.

 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Clario. (2019, June 19). BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20140616/BioClinica-announces-acquisition-of-Blueprint-Clinical-to-drive-RBM-strategies-for-clinical-trials.aspx.

  • MLA

    Clario. "BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20140616/BioClinica-announces-acquisition-of-Blueprint-Clinical-to-drive-RBM-strategies-for-clinical-trials.aspx>.

  • Chicago

    Clario. "BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials". News-Medical. https://www.news-medical.net/news/20140616/BioClinica-announces-acquisition-of-Blueprint-Clinical-to-drive-RBM-strategies-for-clinical-trials.aspx. (accessed November 24, 2024).

  • Harvard

    Clario. 2019. BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20140616/BioClinica-announces-acquisition-of-Blueprint-Clinical-to-drive-RBM-strategies-for-clinical-trials.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BioClinica expands presence in Europe